Chen Ming-fei, Li Ru-cheng, Chen Chang-hong, Gao Xiao-ci
Department of Infectious Diseases, Affiliated Hospital of Guangdong Medical College, Zhanjiang 524001, China.
Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):718-9, 722.
To observe the therapeutic effects of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy.
Eighty-five patient with liver cirrhosis complicated by hepatic encephalopathy were divided into therapy group (n=45) and control group (n=40). Patients in the control group were treated with routine comprehensive therapy, and those in the therapy group received additional intravenous administration with 40 ml L-ornithine-L-aspartate in 250 ml 10% glucose and saline (once daily, 7 days for a treatment course).
L-ornithine-L-aspartase significantly decreased blood ammonia and improved hepatic function (P<0.05 or 0.01). The therapeutic effects of therapy group was better than that of the control group (P<0.05), and no significant side effect was observed in L-ornithine-L-aspartate treatment.
L-ornithine-L-aspartate is effective for hepatic encephalopathy and has not obvious side effect.
观察L-鸟氨酸-L-天冬氨酸治疗肝硬化并发肝性脑病的疗效。
将85例肝硬化并发肝性脑病患者分为治疗组（n = 45）和对照组（n = 40）。对照组采用常规综合治疗，治疗组在此基础上给予40 ml L-鸟氨酸-L-天冬氨酸加入250 ml 10%葡萄糖氯化钠溶液中静脉滴注（每日1次，7天为1个疗程）。
L-鸟氨酸-L-天冬氨酸能显著降低血氨水平，改善肝功能（P<0.05或0.01）。治疗组疗效优于对照组（P<0.05），且L-鸟氨酸-L-天冬氨酸治疗未观察到明显副作用。
L-鸟氨酸-L-天冬氨酸治疗肝性脑病有效，且无明显副作用。
Zotero 插件